Advanced Theranostic Nanomedicine in Oncology
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (1 September 2022) | Viewed by 499
Special Issue Editors
Interests: drug delivery; cancer; imaging; targeting; biomaterials
Interests: nanomedicine; chemistry; cancer research; molecular imaging; cancer drug delivery; immunomodulatory nanomaterials; theranostics; angiogenesis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite recent advances in oncology research, clinicians lack effective therapeutic methods to treat cancer. The failure to detect cancer in the early stages of disease is one of the foremost reasons for inefficient therapies. Most current therapeutics show poor bioavailability, least effect at the target site, and adverse side effects. Recent signs of progress in the drug delivery field hold the potential for enhancing early diagnosis and therapeutic benefits by offering combination drug/imaging agents loading and minimizing chemotherapy-associated side effects. Nanoformulation-based anticancer therapies have been successful in recent years and have become increasingly attractive over the past few decades. There is rising assurance that nanotechnology applied to medicine will advance cancer diagnosis and treatment.
The main aim of this Special Issue is to reflect the significance of this developing and fast-evolving oncology research field to highlight recent developments leading to potential clinical applications of these nanoformulations in the diagnosis, prevention, and treatment of cancer. We will focus on recently advanced nanoplatforms for the early detection and treatment of cancer in the present Special Issue. We welcome submissions that describe the most innovative nanotechnologies for early cancer detection and effective treatment.
Dr. Vijay Sagar Madamsetty
Dr. Sudip Mukherjee
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug delivery
- cancer
- imaging
- targeting
- biomaterials
